IPC flags adverse reaction linked to antihypertensive drug Losartan
New Delhi: The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of February, has revealed that popular antihypertensive drug, Losartan is linked with Adverse Drug Reactions (ADRs), Muscle Spasm.
This came after preliminary analysis of Adverse Drug Reactions (ADRs) from the Pharmacovigilance Programme of India (PvPI) database.
Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Losartan reversibly and competitively prevents angiotensin II binding to the AT1 receptor in tissues like vascular smooth muscle and the adrenal gland. Losartan and its active metabolite bind the AT1 receptor with 1000 times more affinity than they bind to the AT2 receptor. The active metabolite of losartan is 10-40 times more potent by weight than unmetabolized losartan as an inhibitor of AT1 and is a non-competitive inhibitor. Losartan's prevention of angiotensin II binding causes vascular smooth muscle relaxation, lowering blood pressure.
Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.
Following the preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database, it is reported that Losartan can lead to Muscle Spasm. Muscle spasms (muscle cramps) are painful contractions and tightening of your muscles. They're common, involuntary and unpredictable.
Now, as per the issued drug safety alert, the following suspected drug is associated with the ADRs as given below:
Sl. No. | Suspected Drug | Indication | Adverse Drug Reaction |
1. | Losartan | For the treatment of hypertension | Muscle Spasm |
In light of the above, the Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, has advised Healthcare Professionals, Patients/Consumers to closely monitor the possibility of the above ADRs associated with the use of above suspected drugs.
Further, the safety alert added, "If such reaction is encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (http://www.ipc.gov.in), through Android Mobile App "ADR PvPI App" and PvPIHelpline No. 1800-180-3024 (Toll Free)."
